Urenco Annual Report 2022

3 Urenco Annual report and accounts 2022 Inputs Outputs Financial outcomes Non-financial outcomes 1 EBITDAisdefinedasearningsbeforeexceptionalitems,interest(includingother financecosts),taxation,depreciationandamortisationandjointventureresults. Depreciationandamortisationareadjustedtoremoveelementsofsuchcharges includedinchangestoinventoriesandSWUassetsandnetcostsofnuclear provisions.Areconciliationtoincomefromoperatingactivities(pre-exceptional items)issetoutonpage122. 2 Capitalexpenditureincludesnetcashflowsonthepurchasesofproperty,plant andequipmentandintangibleassetsof€166.6millionandonthedecreaseof capitalaccrualsof€17.4million(includedinworkingcapitalpayables). Capital expenditurefortheyearended31December2021hasbeenrepresentedfrom €129.8millionto€142.3millionandcomprisednetcashflowsonthepurchasesof property,plantandequipmentandintangibleassetsof€143.5millionandonthe increaseofcapitalaccrualsof€1.2million(includedinworkingcapitalpayables). 3 AsaproportionofthenuclearcarbonoffsetascalculatedbytheIEA. Strategic report 01 • Integrated and diverse nuclear fuel supplier helping to deliver energy security • Advancement of the evolution of the nuclear fuel cycle through the development of next generation fuels • Commitment to meet net zero emissions within our direct operations by 2030 and our wider supply chain by 2040 • Reliable transatlantic transportation services • Enhanced stable isotopes offering for medical, industrial and research applications • Responsible nuclear stewardship, including materials management and decommissioning • Over 1,700 highly skilled and well-trained employees • Leading centrifuge technology • Excellence in safe operations and maintenance • Research and development • Strong customer service • Rigorous supplier and compliance audits • Detailed market intelligence • Robust commitment to nuclear safeguards and non-proliferation through the Treaties of Almelo, Washington and Cardiff and Government oversight • Revenue: €1,716.5million (2021: €1,669.3million) • EBITDA 1 : €824.6million (2021: €971.1 million) • Net income: €1, 173.2million post exceptional, €285.1 million pre exceptional (2021: €364.5million post exceptional) • Cash generated fromoperations: €1,133.7million (2021: €1,027.6million) • Capital expenditure: €184.0million (2021: €142.3million) 2 • Net cash was €627.2million (2021: net debt €11.5million) • Contract order book: approximate value of €10.8 billion, extending into the 2030s • Safety performance – strong compared to external peers; Total Recordable Injury Rate (TRIR) of 0.445 resulting in 11 total recordable injuries. (2021: TRIR 0.27) • More than 50 customers in 19 countries • Global enrichment capacity of 17.900 tSW/a • 100%of customer deliveries met • Enriched enough uranium to generate an estimated 780,000 GWh of electricity from nuclear power, avoiding approximately 320million tonnes of carbon emissions • Carbon emissions increased by 4.8% (scope 1 and 2 – direct operations) from 2021 (using location-based emissions factors), but fell by 25.4% from 2019 baseline year 3 • The volume of our annual stable isotopes sales equates to approximately two million patient treatments being performed using medical radioisotopes produced from our products • Our Global ‘Richie’ STEM education programme is estimated to have reached more than 47,000 schoolchildren • Global social impact partnerships established supporting environmental, health and educational goals NEXT GENERATION FUELS